Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Portugal

Health, medical devices, pharmaceutics area and the new branches of science such as biotechnology raise several legal issues and show a high complexity and specificity.

The diversity of entities involved in this sector, the existing regulation and the own operation of the market require from the lawyers a strong knowledge of the specificities of this area. Our team works in particular within the following areas:

  • Regulation
  • Licensing
  • Finance / Mergers and acquisitions
  • Business restructuring
  • Litigation
  • Clinical research
  • Distribution
  • Patents protection and enforcement
  • Labelling
  • Safety and Health
  • Competition
  • Public offers
  • Environment
  • Immigration

We have a multidisciplinary team with a strong curriculum in pharmaceutical area and well positioned to give an answer to the several intervening players in this sector.

Read more Read less

Feed

Show only
27 Mar 20
Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for...
The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...
26 Mar 20
European Com­mis­sion pro­poses delay­ing the May 2020 ap­plic­a­tion of...
The European Com­mis­sion has con­firmed it is work­ing on a pro­pos­al to delay for one year the date of ap­plic­a­tion of the new EU Med­ic­al Devices Reg­u­la­tion 2017/745/EU (the “MDR”) in light of the Cov­id-19...
17 Mar 20
While doc­tors fight COV­ID-19 au­thor­it­ies battle fraud, price hikes...
In every coun­try hit by COV­ID-19, the dis­ease linked to the Coronavir­us, com­pet­i­tion and con­sumer pro­tec­tion au­thor­it­ies have been con­fron­ted with the vir­us's im­plic­a­tions. Gov­ern­ments, au­thor­it­ies and...
10 Mar 20
EU Com­mis­sion's White Pa­per on Ar­ti­fi­cial In­tel­li­gence stresses ex­cel­lence...
Ar­ti­fi­cial in­tel­li­gence (AI) has now reached al­most all areas of life: mo­bil­ity, trade and health, to name but a few. As a res­ult, the EU Com­mis­sion has sum­mar­ised its vis­ion for the fu­ture of AI and...
06 Mar 20
MDR - Agree­ments with third party con­tract man­u­fac­tur­ers
The EU Med­ic­al Device Reg­u­la­tion, which comes in­to force on 26 May 2020, will lead not only to big changes in how med­ic­al devices are reg­u­lated, but also to more thought be­ing giv­en to agree­ments between...
28 Feb 20
Pat­ent­ing Ar­ti­fi­cial In­tel­li­gence and quantum tech­no­lo­gies
IP and Life Sci­ence ana­lys­is: Caitlin Heard, IP Lit­ig­a­tion Part­ner, and Rachel Free, Pat­ent At­tor­ney and Part­ner, at CMS Camer­on McK­enna, dis­cuss the ap­plic­ab­il­ity of Ar­ti­fi­cial In­tel­li­gence (AI) and...
26 Feb 20
Can­nabis mark ruled con­trary to pub­lic policy
Back­ground On 19 Decem­ber 2016, Ms Santa Conte (“Ms Conte”) made an ap­plic­a­tion to re­gister an EU trade mark for the fol­low­ing fig­ur­at­ive sign in re­la­tion to vari­ous food and drink products and ser­vices...
31 Jan 20
UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
17 Jan 20
New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
15 Jan 20
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
23 Dec 19
So­cial Me­dia and mHealth Data EMA / HMA Re­port
New and in­nov­at­ive tech­no­lo­gies have led to a huge in­crease in data com­ing from sources that haven’t pre­vi­ously been used with­in the reg­u­lated medi­cines in­dustry. In re­cog­ni­tion of this ex­plo­sion of...
20 Dec 19
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...